Avanos Medical, Inc. (NYSE:AVNS - Free Report) - Equities research analysts at Zacks Research lowered their Q3 2025 EPS estimates for shares of Avanos Medical in a research report issued to clients and investors on Wednesday, March 19th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.30 per share for the quarter, down from their prior estimate of $0.43. The consensus estimate for Avanos Medical's current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical's FY2025 earnings at $1.20 EPS, Q2 2026 earnings at $0.30 EPS and FY2026 earnings at $1.48 EPS.
Avanos Medical (NYSE:AVNS - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.03. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. The business had revenue of $179.60 million during the quarter, compared to the consensus estimate of $177.23 million.
Separately, StockNews.com upgraded Avanos Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, March 19th.
Read Our Latest Research Report on Avanos Medical
Avanos Medical Trading Up 1.1 %
Shares of AVNS traded up $0.16 during trading hours on Monday, reaching $14.32. 353,567 shares of the company traded hands, compared to its average volume of 295,990. The company's fifty day moving average price is $15.73 and its two-hundred day moving average price is $18.48. The company has a quick ratio of 1.46, a current ratio of 2.22 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $658.62 million, a price-to-earnings ratio of 42.11 and a beta of 1.17. Avanos Medical has a 12 month low of $14.02 and a 12 month high of $25.36.
Hedge Funds Weigh In On Avanos Medical
A number of hedge funds have recently added to or reduced their stakes in AVNS. T. Rowe Price Investment Management Inc. grew its position in shares of Avanos Medical by 27.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company's stock worth $47,941,000 after buying an additional 644,267 shares during the last quarter. Tributary Capital Management LLC raised its position in Avanos Medical by 38.1% during the 4th quarter. Tributary Capital Management LLC now owns 893,008 shares of the company's stock worth $14,217,000 after buying an additional 246,379 shares during the last quarter. Brown Advisory Inc. raised its holdings in shares of Avanos Medical by 12.0% during the fourth quarter. Brown Advisory Inc. now owns 1,905,094 shares of the company's stock worth $30,329,000 after purchasing an additional 204,218 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its stake in shares of Avanos Medical by 43.1% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 494,627 shares of the company's stock worth $7,874,000 after buying an additional 148,902 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Avanos Medical by 189.8% in the 4th quarter. JPMorgan Chase & Co. now owns 201,634 shares of the company's stock worth $3,210,000 after purchasing an additional 132,063 shares in the last quarter. 95.17% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In related news, SVP Kerr Holbrook sold 7,000 shares of the firm's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $15.25, for a total value of $106,750.00. Following the completion of the transaction, the senior vice president now directly owns 82,047 shares of the company's stock, valued at approximately $1,251,216.75. This trade represents a 7.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 2.90% of the company's stock.
About Avanos Medical
(
Get Free Report)
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
See Also
Before you consider Avanos Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avanos Medical wasn't on the list.
While Avanos Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
